EIF2AK3 and hepatocellular carcinoma: Sorafenib itself may contribute to ZFAS1 activation by activating PERK/ATF4-pathways in drug-resistant HCC cells and inhibiting the PERK-signaling pathway, which has been suggested to re-sensitize cells to sorafenib [42].